Literature DB >> 26794438

Diabetes: Intravitreous ranibizumab for proliferative diabetic retinopathy.

Jonathan M Gibson1, Samantha McGinnigle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26794438     DOI： 10.1038/nrendo.2016.1

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  7 in total

1.  Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Authors:  Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

2.  Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

3.  A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

Authors:  Michel Michaelides; Andrew Kaines; Robin D Hamilton; Samantha Fraser-Bell; Ranjan Rajendram; Fahd Quhill; Christopher J Boos; Wen Xing; Catherine Egan; Tunde Peto; Catey Bunce; R David Leslie; Philip G Hykin
Journal:  Ophthalmology       Date:  2010-04-22       Impact factor: 12.079

4.  Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

5.  Ten years after the Diabetic Retinopathy Study.

Authors:  S L Fine; A Patz
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

Review 6.  Prevalence of vascular complications and factors predictive of their development in young adults with type 1 diabetes: systematic literature review.

Authors:  Steven James; Robyn Gallagher; Janet Dunbabin; Lin Perry
Journal:  BMC Res Notes       Date:  2014-09-02

7.  Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.

Authors:  Sobha Sivaprasad; A Toby Prevost; James Bainbridge; Rhiannon Tudor Edwards; David Hopkins; Joanna Kelly; Phil Luthert; Caroline Murphy; Jayashree Ramu; Negin Sarafraz-Shekary; Joana Vasconcelos; Beverley White-Alao; Philip Hykin
Journal:  BMJ Open       Date:  2015-09-14       Impact factor: 2.692
  7 in total
  2 in total

Review 1.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

2.  Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers.

Authors:  Hao Li; Wenzhong Liu; Christine M Sorenson; Nader Sheibani; Daniel M Albert; Thulani Senanayake; Serguei Vinogradov; Jack Henkin; Hao F Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.